Anti-Hypertensive Drugs - Africa

Africa

The Anti-Hypertensive Drugs market in Africa is predicted to witness a substantial rise in revenue, with projections indicating a staggering amount of US$228.80m in 2024.
Moreover, experts anticipate a steady annual growth rate of 0.32% between 2024 and 2029, culminating in a market volume of US$232.50m by the end of the latter year.
When comparing the global landscape, it is noteworthy that United States is expected to generate the highest revenue, reaching an impressive US$12,290.00m in 2024.
As an AI language model, I can provide you with a country-specific statement about current trends in the market of Anti-Hypertensive Drugs in Africa: In Nigeria, the demand for affordable generic anti-hypertensive drugs has increased due to the rising prevalence of hypertension in the country.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Africa has been on the rise due to several reasons.

Customer preferences: High blood pressure is a common health issue in Africa, and people are becoming more aware of the importance of managing it. The preference for Anti-Hypertensive Drugs has increased as people are seeking effective treatments to control their blood pressure levels. Additionally, the growing aging population in Africa has contributed to the demand for Anti-Hypertensive Drugs.

Trends in the market: The African Anti-Hypertensive Drugs market is experiencing a shift from branded to generic drugs due to their affordability and availability. The market is also witnessing an increase in the production of locally manufactured drugs, which is driving down the cost of Anti-Hypertensive Drugs. Furthermore, the market is becoming more competitive with the entry of new players, which is leading to innovation and the development of new drugs.

Local special circumstances: The African market is diverse, and each country has its own unique circumstances that affect the demand for Anti-Hypertensive Drugs. For instance, in countries with a high burden of communicable diseases, the demand for Anti-Hypertensive Drugs may be lower. On the other hand, countries with a high prevalence of non-communicable diseases such as hypertension may have a higher demand for Anti-Hypertensive Drugs.

Underlying macroeconomic factors: The African market is characterized by low-income levels, which affects the affordability of Anti-Hypertensive Drugs. However, the market is also experiencing economic growth, which is driving up the demand for healthcare services, including Anti-Hypertensive Drugs. The African pharmaceutical industry is also growing, which is creating opportunities for local manufacturers to produce affordable Anti-Hypertensive Drugs. Additionally, the African market is becoming more attractive to international pharmaceutical companies due to the growing demand for healthcare services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.